Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19

Harmony R. Reynolds; Samrachana Adhikari; Claudia Pulgarin; Andrea B. Troxel; Eduardo Iturrate; Stephen B. Johnson; Anaïs Hausvater; Jonathan Newman; Jeffrey S. Berger; Sripal Bangalore; Stuart D. Katz; Glenn I. Fishman; Dennis Kunichoff; Yu Chen; Gbenga Ogedegbe; Judith S. Hochman

doi:10.1056/nejmoa2008975

Abstract

We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications.

Keywords

Renin–angiotensin systemAldosteroneCoronavirus disease 2019 (COVID-19)Internal medicineMedicinePharmacologyBlood pressure

Related Publications

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

Muthiah Vaduganathan , Orly Vardeny , Thomas Michel +3 more

RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncer...

2020 New England Journal of Medicine 2138 citations

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

Giuseppe Mancia , Federico Rea , Monica Ludergnani +2 more

In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence o...

2020 New England Journal of Medicine 1098 citations

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2

Carlos M. Ferrario , Jewell A. Jessup , Mark C. Chappell +5 more

Background— Angiotensin-converting enzyme 2 (ACE2) has emerged as a novel regulator of cardiac function and arterial pressure by converting angiotensin II (Ang II) into the vaso...

2005 Circulation 1598 citations

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Aram V. Chobanian , George L. Bakris , Henry R. Black +8 more

"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure" provides a new guideline for hypertension prevent...

2003 JAMA 25378 citations

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

Laxminarayan G. Hegde , Cecile Yu , Travis Renner +11 more

Dual inhibition of angiotensin-converting enzyme (ACE) and neprilysin (NEP) by drugs such as omapatrilat produces superior antihypertensive efficacy but cause high incidence of ...

2011 Journal of Cardiovascular Pharmacology 63 citations

Publication Info

Year: 2020
Type: article
Volume: 382
Issue: 25
Pages: 2441-2448
Citations: 1098
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1098

OpenAlex

Cite This

APA Style

                            
                                
                                    Harmony R. Reynolds, 
                                
                                    Samrachana Adhikari, 
                                
                                    Claudia Pulgarin
                                
                                et al.
                            
                            (2020). 
                            Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. 
                            New England Journal of Medicine
                            , 382
                            (25)
                            , 2441-2448.
                            https://doi.org/10.1056/nejmoa2008975
                        

Identifiers

DOI: 10.1056/nejmoa2008975